Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Very High Risk Myelodysplastic Syndrome”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Ended earlyNCT02929498
What this trial is testing

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromeMyelodysplastic Syndromes
GlaxoSmithKline 7
Testing effectiveness (Phase 2)Study completedNCT04103879
What this trial is testing

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

Who this might be right for
High Risk Hematological MalignancyCord Blood Transplant
ExCellThera inc. 30
Testing effectiveness (Phase 2)UnknownNCT03454984
What this trial is testing

SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 40
Testing effectiveness (Phase 2)Ended earlyNCT03151304
What this trial is testing

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Helsinn Healthcare SA 64
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Looking for participantsNCT06612944
What this trial is testing

Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification

Who this might be right for
Myelodysplastic Syndromes, Adult
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 40
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT02920541
What this trial is testing

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)
Institut de Recherches Internationales Servier 48
Testing effectiveness (Phase 2)Looking for participantsNCT05601726
What this trial is testing

First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

Who this might be right for
Acute Myeloid Leukemia, AdultMyelodysplastic Syndromes
Advanced BioDesign 36
Testing effectiveness (Phase 2)Ended earlyNCT04812548
What this trial is testing

Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 20
Early research (Phase 1)Ended earlyNCT05961839
What this trial is testing

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaHigh-Risk and Very High-Risk Myelodysplastic Syndromes
Schrödinger, Inc. 66
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07387354
What this trial is testing

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromesMDSMyelodysplastic Syndrome, Unclassifiable+3 more
Thomas Jefferson University 25
Early research (Phase 1)Looking for participantsNCT03630991
What this trial is testing

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more
M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Ended earlyNCT05835011
What this trial is testing

Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Astex Pharmaceuticals, Inc. 2
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Large-scale testing (Phase 3)UnknownNCT05175508
What this trial is testing

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Who this might be right for
AMLMDSOld Age; Debility+1 more
The First Affiliated Hospital of Soochow University 180
Early research (Phase 1)Looking for participantsNCT04275518
What this trial is testing

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc. 102